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Bladder leiomyosarcoma: Partial cystectomy and complementary treatment
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Objective. We report a new case of bladder leiomyosarcoma in an elderly patient. Bladder leiomyosarcoma is an infrequent
malignancy, representing less than 1% of all bladder neoplasms. Nevertheless, among the range of mesenchymal tumors,
leiomyosarcoma is the most common lesion found in the bladder.
Methods. A 75-year-old male presented with a history of moderate chronic obstructive pulmonary disease and no other medical
antecedents of interest. The patient reported to the emergency Service with urethral bleeding and urinary retention. Since
urethral catheterization did not prove possible, a suprapubic catheter was placed, followed by evaluation of the case. Ultrasound
revealed a large distended bladder with an apparent single diverticulum of a size similar to that of the bladder itself (over
13 cm in maximum diameter), with several wall polypoid images measuring under 2–3 cm in size both in the bladder and in the
diverticulum, suggestive of a bladder neoplastic process. In view of the ultrasound ﬁndings and urethral stenosis, an ureterotomy
was performed with cystoscopy which revealed a solid calciﬁed tumor measuring almost 7 cm in size, located on the lateral wall.
Transurethral resection was performed in the same surgical intervention, leaving residual tumor.
Results. Based on these results, the decision was taken to complete surgery, opting for partial cystectomy and diverticulectomy,
with the following histological ﬁndings: Low-grade leiomyosarcoma (3 mitotic ﬁgures per 10 high-magniﬁcation ﬁelds), with
marked cellular pleomorphism. With the diagnosis of low-grade leiomyosarcoma with invasion of all the layers, the case was
evaluated by the clinical committee, which decided to provide adjuvant therapy in view of the high risk condition of the patient.
The study of disease spread was moreover completed with a chest and abdominal CAT scan, bone gammagraphy and pelvic MRI,
which showed no distant spread. Locoregional radiotherapy (dosage 57Gy) and complementary chemotherapy were provided.
Chemotherapy consisted of a combination of ifosfamide and adriamycin at the usual doses, in the form of three treatment
cycles. Following treatment, the patient was subjected to strict follow-up with periodic cystoscopy, urinary cytology and chest-
abdominal-pelvic CAT scans. After a period of 30 months, he remains free of disease
Conclusion. Bladder leiomyosarcoma is an infrequent tumor in which complete surgical resection remains the management
option of choice. Of note in the present case is the use of conservative surgery, which is regarded as feasible provided the entire
neoplasm is removed. The role of neoadjuvant chemotherapy with a view to facilitating resection or a partial cystectomy should
be evaluated in tumors of this kind. Chemotherapy and radiotherapy after partial surgical resection appears to be acceptable in
order to reduce the risk of relapse.
http://dx.doi.org/10.1016/j.rpor.2013.03.478
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Introduction. Laboratory studies have shown signiﬁcant advantages of neoadjuvant hormone therapy (HT) to radiotherapy (RT) in
prostate cancer (PC) as a result of its boosting and supra-additive effect. It also slows cell division and reduces tumor hypoxia.
Very low PSA values with HT before radiotherapy could reduce time on HT.
Objectives. To present options recommended by radiation oncologists in the most controversial aspects of treating PC using
neoadjuvant aLHRH in 4 typical patients: 2 with intermediate-risk (IR) disease and 2 with high-risk (HR) disease, with(out)
cardiovascular comorbidity.
Methods. The ÁGORA project involved 18 oncologists and comprised 4 phases: (1) selection of the most controversial issues in
treatment of PC using neoadjuvant aLHRH; (2) selection of the most relevant published scientiﬁc articles; (3) preparation of case
reports; (4) critical reading of the articles and discussion of the case reports at regional meetings (May–July 2011). Therapeutic
procedureswere classiﬁed as “highly recommendable”, “recommendable in some cases”, or “not recommendable/not applicable”.
The dispersion of the responses was considered to indicate consensus (SD<0.15) or high variability (SD>0.85).
Results. In patients with IR with(out) a cardiovascular history, HT was not recommendable in some cases (SD 0.14). Sixteen of the
18 oncologists did not agree with neoadjuvant HT. In patients with HR disease and no history of severe cardiovascular events and
>1 unfavorable risk factor, no participants rejected long-term HT (24–36 months). Half did not recommend adapting the duration
of HT to the response to neoadjuvant HT. In the HR patient aged 65 years with cardiovascular problems and >1 unfavorable risk
factor, no consensus was reached on the role of HT, although most participants (14/18) did not reject it. Ten of the 18 participants
considered that neoadjuvant HT could be administered until PSA reached <0.1. The only short-term regimen recommended in
this group was that of D’Amico (13/18).
